A Phase 3 interventional study of APD421 and Placebo in PONV, sponsored by Acacia Pharma Ltd. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-20.
Sponsored by Acacia Pharma Ltd · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing amisulpride in Postoperative Nausea and Vomiting — 2 open to participants now, 2 under way, none of them phase 3. Amisulpride · Postoperative Nausea and Vomiting.
Among the 11 studies testing amisulpride in Postoperative Nausea and Vomiting, this one is the 7th largest by enrollment, is one of 2 that started in 2013, is one of 6 in phase 3, and was the 2nd registered.
638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.
Browse Postoperative Nausea and Vomiting studies →2 of the 11 studies testing amisulpride in Postoperative Nausea and Vomiting are open now, in 1 country. Recruiting first, the newest first:
Qianfoshan Hospital
Ages 18–75
Sir Run Run Shaw Hospital · Sites in China
Ages 18–65 · Women only
By country, each count listing its studies:
Amisulpride: first FDA approval 2020 (BARHEMSYS). What it is approved for, and how studies give it, is on its page →
Of the 66 Postoperative Nausea and Vomiting studies recruiting now, 22 (33%) set no upper age limit and 38 (58%) stop at 75 or younger; 15 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 7
First in 2012; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 368 is above the median of 112 across 529 interventional studies indexed under Postoperative Nausea and Vomiting.
Median enrollment 453 across the 11 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 4 most frequent:
Acacia Pharma Ltd is the lead sponsor of 18 studies on the registry; none are open to participants now.
10 studies in Postoperative Nausea and Vomiting by Acacia Pharma Ltd: none open now, none under way, none of them phase 3. Of 9 finished, 7 (78%) have results posted.
Among the 10 studies in Postoperative Nausea and Vomiting by Acacia Pharma Ltd, this one is one of 2 that started in 2013, is one of 5 in phase 3, and was the 3rd registered.
Acacia Pharma Ltd’s Postoperative Nausea and Vomiting studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing amisulpride in Postoperative Nausea and Vomiting, from their registry updates:
Among Acacia Pharma Ltd’s 10 in Postoperative Nausea and Vomiting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
IV APD421 single dose
Drug: APD421
IV placebo single dose
Drug: Placebo
Complete Response (no Emesis, Significant Nausea or Rescue Medication)
The primary efficacy analysis was a comparison of the incidence of Complete Response (absence of PONV1) in the 0-24-hour period after surgery, between the active treatment group and the placebo group using Pearson square test with Yates's continuity correction at a two-sided significance level of 5%.
Time frame: 24 hours after end of surgery
Complete Response (no Emesis or Rescue Medication)
Time frame: 24 hrs after end of surgery
Total Response (no Emesis, Nausea or Rescue Medication)
Time frame: 24 hrs after end of surgery
Incidence of Emesis (Vomiting/Retching)
An assessment of a participant experiencing an episode of emesis (vomiting/ retching) or received anti-emetic rescue medication during the 24hours after the completion of the surgery
Time frame: 24 hours after end of surgeryry
Incidence of Nausea
Count of patients experiencing an episode of nausea scored ≥ 1 of 0-10 verbal response scale during the 24 hours period after the completion of surgery
Time frame: 24 hours after end of surgery
Incidence of Significant Nausea
Count of participants with nausea score ≥ 4 on 0-10 verbal response scale
Time frame: 24 hours after end of surgery
Use of Rescue Medication
Time frame: 24 hours after end of surgery
| Milestone | APD421 | Placebo |
|---|---|---|
| Started | 169 | 178 |
| Completed | 6 | 11 |
| Not completed | 163 | 167 |
The primary efficacy analysis was a comparison of the incidence of Complete Response (absence of PONV1) in the 0-24-hour period after surgery, between the active treatment group and the placebo group using Pearson square test with Yates's continuity correction at a two-sided significance level of 5%.
| Participants | APD421 | Placebo |
|---|---|---|
| Complete Response (no Emesis, Significant Nausea or Rescue Medication) | 95 | 83 |
| Participants | APD421 | Placebo |
|---|---|---|
| Complete Response (no Emesis or Rescue Medication) | 100 | 89 |
| Participants | APD421 | Placebo |
|---|---|---|
| Total Response (no Emesis, Nausea or Rescue Medication) | 87 | 73 |
An assessment of a participant experiencing an episode of emesis (vomiting/ retching) or received anti-emetic rescue medication during the 24hours after the completion of the surgery
| Participants | APD421 at 5mg | Placebo |
|---|---|---|
| Incidence of Emesis (Vomiting/Retching) | 34 | 46 |
Count of patients experiencing an episode of nausea scored ≥ 1 of 0-10 verbal response scale during the 24 hours period after the completion of surgery
| Participants | APD421 at 5mg | Placebo |
|---|---|---|
| Incidence of Nausea | 75 | 98 |
Count of participants with nausea score ≥ 4 on 0-10 verbal response scale
| Participants | APD421 | Placebo |
|---|---|---|
| Incidence of Significant Nausea | 63 | 84 |
| Participants | APD421 | Placebo |
|---|---|---|
| Use of Rescue Medication | 62 | 82 |
Collected over Any AE that is serious occurring during the course of the study, irrespective of the treatment received by the subject must be reported to the pharmacovigilance provider within 24hours of it's recognition. Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| APD421 at 5mg | 0/169 (0%) | 3/169 (1.8%) | 91/169 (53.8%) |
| Placebo | 0/178 (0%) | 4/178 (2.2%) | 178/178 (100%) |
| Event | APD421 at 5mg | Placebo |
|---|---|---|
| Anastomic LeakInjury, poisoning and procedural complications | 1/169 | 0/178 |
| Portal Vein ThrombosisHepatobiliary disorders | 1/169 | 0/178 |
| AdenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/169 | 0/178 |
| Gastrointestinal Stoma ComplicationInjury, poisoning and procedural complications | 0/169 | 1/178 |
| Post Procedural HaemorrhageInjury, poisoning and procedural complications | 0/169 | 1/178 |
| PresyncopeNervous system disorders | 0/169 | 1/178 |
| HaemorrhageVascular disorders | 0/169 | 1/178 |
| Event | APD421 at 5mg | Placebo |
|---|---|---|
| Procedural PainInjury, poisoning and procedural complications | 91/169 | 92/178 |
| NauseaGastrointestinal disorders | 20/169 | 18/178 |
| FlatulenceGastrointestinal disorders | 18/169 | 16/178 |
| Blood Prolactin IncreasedInvestigations | 18/169 | 2/178 |
| ConstipationGastrointestinal disorders | 16/169 | 9/178 |
| HeadacheNervous system disorders | 14/169 | 9/178 |
| HypotensionVascular disorders | 9/169 | 14/178 |
| AnaemiaBlood and lymphatic system disorders | 10/169 | 9/178 |
| Sleep DisorderPsychiatric disorders | 7/169 | 9/178 |
| Age, Continuous(Years) | APD421 | Placebo | Total |
|---|---|---|---|
| Mean | 51.7 ± 16.2 | 51.6 ± 14.9 | 51.6 ± 15.5 |
| Sex: Female, Male(Participants) | APD421 | Placebo | Total |
|---|---|---|---|
| Female | 147 | 154 | 301 |
| Male | 22 | 24 | 46 |
The record gives a start of Jul 2013, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2019, 5 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amisulpride
Postoperative Nausea and Vomiting →
Acacia Pharma Ltd